Table 1a.
Type I |
Type II |
Type III |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Groups | R(%) | P1 | P2 | R(%) | P1 | P2 | R(%) | P1 | P2 | ||
Full-dose sIPV | 100 | — | 0.001 | 50 | — | 0.001 | 60 | — | NS | ||
1/4-dose sIPV | 20 | 0.001 | — | 0 | 0.001 | — | 20 | NS | — | ||
1/4-dose+AS03 | 100 | NS | 0.001 | 100 | NS | 0.000 | 100 | 0.011 | 0.001 | ||
1/4-dose+BW006 | 100 | NS | 0.001 | 50 | NS | 0.033 | 60 | NS | NS | ||
1/4-dose+Poly:IC | 70 | NS | NS | 0 | 0.001 | NS | 0 | NS | NS | ||
1/4 dose+AS03+ BW006 | 100 | NS | 0.001 | 100 | NS | 0.000 | 100 | 0.011 | 0.001 | ||
Total | P = 0.011 | P = 0.000 | P = 0.000 |
Note: Seroconversion refers to a reciprocal antibody titer of 8 or higher. Data are proportion(%) of subjects with seroconversion(n = 10).
p1 values are compared with the full-dose group, p2 values are compared with the 1/4-dose group. NS denotes not significant.